CWC
ARCT icon

Carolinas Wealth Consulting’s Arcturus Therapeutics ARCT Stock Holding History

Carolinas Wealth Consulting’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16
Closed -$505 – 1042
2023
Q4 		$505 Buy
+16
New +$380 ﹤0.01% 918

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carolinas Wealth Consulting's ARCT Position: Q1 2024 in Review

Carolinas Wealth Consulting sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 16 shares — an estimated $505 sold.

Carolinas Wealth Consulting first reported a position in ARCT in Q4 2023 and held it in 1 quarter. The position peaked at $505 in Q4 2023. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Carolinas Wealth Consulting reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 16 Arcturus Therapeutics shares in Q1 2024, an estimated $505.
  • Carolinas Wealth Consulting first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Arcturus Therapeutics position peaked at $505 in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2024, filed 15 May 2024.